Hawkins, Inc. (HWKN) Stock Price & How to Invest

Hawkins, Inc. (NASDAQ: HWKN) is a specialty chemicals company founded in 1938 and headquartered in Roseville, Minnesota. It operates through three segments: Water Treatment (chemicals, equipment, and services for potable water, municipal and industrial wastewater, pools, and agriculture), Industrial (chemicals and blends for food, pharmaceutical, energy, electronics, and plating customers), and Health and Nutrition (ingredient distribution and formulation for supplements, functional foods, and personal care). Water Treatment has become the growth engine, expanded aggressively through a string of regional acquisitions such as WaterSurplus, and in September 2026 Hawkins added Dave Symonds & Associates in Florida and Eagle Labs in the Dallas-Fort Worth region of Texas.

The investment picture is one of a steady industrial compounder. In fiscal 2026 (ended March 29, 2026) the company crossed $1 billion in revenue for the first time, reaching about $1.08 billion, and extended a dividend streak that now spans more than four decades. Net income was about $81.5 million, slightly below the prior year's $84.3 million. The first quarter of fiscal 2027 (ended June 28, 2026) brought revenue growth of about 7.6% year over year, but EPS of $1.36 fell short of the $1.53 estimate, the third miss in four quarters. The tradeoff for investors is valuation: even after the stock fell from a 52-week high of about $174 to around $133, it trades at a meaningful premium to the broader chemicals sector, so returns increasingly depend on continued acquisition execution and margin discipline in the Water Treatment segment rather than on a cheap starting price.

The largest risk is valuation: the stock trades at about 34x trailing and 28x forward earnings, well above the chemicals-industry and peer averages, so any growth disappointment can compress the multiple, as the 21% one-year decline after a string of earnings misses has shown. The acquisition-led strategy carries integration and overpayment risk, and debt of about $258 million against roughly $8 million of cash reflects borrowing to fund deals. The Industrial segment is exposed to raw-material cost swings and pass-through timing that can pressure margins. Health and Nutrition is smaller and more volatile in demand. Finally, the company is relatively small and concentrated in North America, so a single large deal or region can meaningfully affect results.

4 analysts publish price targets on HWKN, averaging $174.00 against a $131.66 price as of October 2026, or +32.2%. The published targets run from $141.00 to $200.00, a moderate spread, and the ratings split 2 buy, 1 hold, 0 sell. Over the last six months there have been 0 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full HWKN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Hawkins, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Water Treatment roll-up. Water Treatment is the fastest-growing segment, up roughly 28% year over year in the first quarter of fiscal 2026. The most optimistic published target, $200.00, assumes this works close to its best case.

The case against. The largest risk is valuation: the stock trades at about 34x trailing and 28x forward earnings, well above the chemicals-industry and peer averages, so any growth disappointment can compress the multiple, as the 21% one-year decline after a string of earnings misses has shown. The most pessimistic target, $141.00, is roughly what HWKN is worth if this bites instead.

Read the full bull and bear case on HWKN, including what would have to change to break either one. Walnut is not an investment adviser.

Yes. Hawkins, Inc. (HWKN) has had one share split in the last 10 years:

• 2:1 on March 2, 2021, so every share held became 2 shares.

A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of HWKN the day before the 2:1 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.

Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Hawkins, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$1.11 billion
• Revenue growth (Q1 FY2027, YoY): ~7.6%
• Net income (TTM): ~$81 million
• Operating / net margin (TTM): ~12% / ~7%
• P/E (trailing / forward): ~34x / ~28x
• EV/EBITDA: ~18x
• Market cap: ~$2.8 billion
• Dividend (annual / yield): ~$0.80 / ~0.6%

The multiple has come down: at about $133, Hawkins trades near 34x trailing earnings and 18x EV/EBITDA, compared with a mid-to-high 30s P/E and roughly 20x EV/EBITDA in mid-2026, still a premium to the US chemicals sector and close peers. Analysts expect only about 4% EPS growth in fiscal 2027 (to about $4.11) before roughly 14% in fiscal 2028. Fiscal Q2 2027 results are due October 26, with consensus EPS of about $1.18 on revenue near $303 million.

Other names that sit close to HWKN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get HWKN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so HWKN sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where HWKN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Hawkins is a durable, dividend-paying water treatment and specialty chemicals operator whose main open question is whether its premium multiple, still about 34x trailing earnings after the 2026 pullback, is justified by acquisition-led growth. Two more water treatment deals in September 2026 show the roll-up is still running.

Whether HWKN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is HWKN a buy or a sell?, and where the stock could go from here in the HWKN stock forecast.

For income investors, whether HWKN pays a dividend and how the payout looks is covered in does HWKN pay a dividend? And to weigh HWKN against a peer, read the full side-by-side comparisons: HWKN vs ECL and HWKN vs IFF.